Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JAMA sees ghost authors

Executive Summary

The June 5 Journal of American Medical Association devoted to peer review issues, includes article on honorary and ghost authorship. Graham Mowatt, University of Aberdeen, et al., examined 362 reviews published in The Cochrane Library and found 9% had evidence of ghost authorship and 39% had evidence of honorary authorship. PhRMA is developing guidelines on disclosing authorship (1"The Pink Sheet" May 13, p. 20)...

You may also be interested in...



PhRMA Firms Will Disclose “Ghost Writers,” Give Credit For Journal Work

Manuscript writers and statisticians provided by drug sponsors to help present results from a clinical trial will be "recognized appropriately" as contributors to publications of the data, according to a draft policy paper on the ethics of clinical trials under development by the Pharmaceutical Research & Manufacturers of America

EU ‘Structured Dialog’ Offers Opportunity To Secure Supply

A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.

Adcock Struggles As South African Healthcare Awaits Relief

Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel